INmune Bio (INMB) Projected to Announce Quarterly Earnings on Thursday

INmune Bio (NASDAQ:INMB) is anticipated to announce its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.2067) per share and revenue of $1.1550 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

INmune Bio (NASDAQ:INMB) last issued its earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04.

INmune Bio Stock Up 5.7%

Shares of NASDAQ INMB opened at $1.85 on Tuesday. The firm’s 50-day moving average price is $1.58 and its 200-day moving average price is $1.47. INmune Bio has a 52-week low of $1.09 and a 52-week high of $2.96. The company has a market cap of $49.17 million, a PE ratio of -1.11 and a beta of 0.97.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in INMB. Quadrature Capital Ltd bought a new position in INmune Bio in the 4th quarter worth $26,000. Intech Investment Management LLC purchased a new stake in INmune Bio in the 2nd quarter worth $26,000. Squarepoint Ops LLC bought a new stake in INmune Bio during the third quarter valued at about $30,000. Virtu Financial LLC bought a new stake in INmune Bio during the fourth quarter valued at about $32,000. Finally, Wells Fargo & Company MN lifted its position in shares of INmune Bio by 79.0% in the fourth quarter. Wells Fargo & Company MN now owns 24,857 shares of the company’s stock valued at $39,000 after acquiring an additional 10,970 shares in the last quarter. Institutional investors own 12.72% of the company’s stock.

Wall Street Analyst Weigh In

INMB has been the subject of a number of research analyst reports. Weiss Ratings raised shares of INmune Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 20th. Wall Street Zen cut INmune Bio from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, INmune Bio presently has an average rating of “Moderate Buy”.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.